Bacteremia Caused by Acinetobacter baumannii: Epidemiologic Features, Antimicrobial Susceptibility, and Outcomes


Acinetobacter baumannii bacteremia is becoming more prevalent and is associated with increasing morbidity and mortality. Escalating antibacterial resistance further contributes to therapeutic dilemmas, enhanced infection control support and poorer outcomes in patients infected with these bacteria. A retrospective analysis of patients whose blood cultures produced A. baumannii from January 2007 through January 2013 was performed. Data regarding the epidemiologic features, antimicrobial susceptibility and outcomes of patients with A. baumannii bacteremia were collected and analyzed. Sixty A. baumannii isolates each from a different patient were identified. The Charlson Comorbidity Index (≥3) was the greatest among patients with multi-drug resistance (MDR) compared to intermediate drug resistance (IDR) and pan-sensitive (PS) A. baumannii. The mean APACHE II scores for MDR, IDR and PS A. baumannii bacteremia were 21, 15 and 11, respectively (P < 0.05, MDR v. PS). Seventy-three percent of the isolates were resistant to quinolones, 44% to piperacillin/tazobactam, 45% to amikacin, 22% to imipenem, 0% to ticarcillin/clavulanate, and 0% to polymyxin. Among 28 patients with MDR A. baumannii bacteremia, 20 received inadequate empiric treatment, and 16 of these patients died (80%). Of the remaining eight patients with MDR bacteremia who received adequate empiric antibiotics, only two died (25%). The severity of underlying illness, degree of antibiotic resistance and receiving inadequate initial antibiotic therapy are associated with mortality among patients with bacteremia due to A. baumannii.

Share and Cite:

Chiang, T. , Pastagia, M. and Huang, D. (2014) Bacteremia Caused by Acinetobacter baumannii: Epidemiologic Features, Antimicrobial Susceptibility, and Outcomes. Advances in Infectious Diseases, 4, 66-71. doi: 10.4236/aid.2014.41011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Park, K.H., Shin, J.H., Lee, S.Y., Kim, S.H., Jang, M.O. and Kang, S.J. (2013) The Clinical Characteristics, Carbapenem Resistance, and Outcome of Acinetobacter bacteremia According to Genospecies. PloS One, 8, 65026.
[2] Huh, K., Kim, J., Cho, S.Y., Ha, Y.E., Joo, E.J., Kang, C.I., Chung, D.R., Lee, N.Y., Song, J.H. and Peck, K.R. (2013) Continuous Increase of the Antimicrobial Resistance among Gram-Negative Pathogens Causing Bacteremia: A Nationwide Surveillance Study by the Korean Network for Study on Infectious Diseases (KONSID). Diagnostic Microbiology and Infectious Disease, 76, 477-482.
[3] Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P. and Edmond, M.B. (2004) Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clinical Infectious Diseases, 39, 309-317.
[4] Wisplinghoff, H., Edmond, M.B., Pfaller, M.A., Jones, R.N., Wenzel, R.P. and Seifert, H. (2000) Nosocomial Bloodstream Infections Caused by Acinetobacter Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial Susceptibility. Clinical Infectious Diseases, 31, 690-697.
[5] Urban, C., Segal-Maurer, S. and Rahal, J.J. (2003) Considerations in Control and Treatment of Nosocomial Infections Due to Multidrug-Resistant Acinetobacter baumannii. Clinical Infectious Diseases, 36, 1268-1274.
[6] Jain, R. and Danziger, L.H. (2004) Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians. Annals of Pharmacotherapy, 38, 1449-1459.
[7] Go, E.S., Urban, C., Burns, J., Kreiswirth, B., Eisner, W., Mariano, N., Mosinka-Snipas, K. and Rahal, J.J. (1994) Clinical and Molecular Epidemiology of Acinetobacter Infections Sensitive Only to Polymyxin B and Sulbactam. Lancet, 344, 1329-1332.
[8] Rahal, J.J., Urban, C. and Segal-Maurer, S. (2002) Nosocomial Antibiotic Resistance in Multiple Gram-Negative Species: Experience at One Hospital with Squeezing the Resistance Balloon at Multiple Sites. Clinical Infectious Diseases, 34, 499-503.
[9] Falagas, M.E., Koletsi, P.K. and Bliziotis, I.A. (2006) The Diversity of Definitions of Multidrug-Resistant (MDR) and Pandrug-Resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. Journal of Medical Microbiology, 55, 1619-1629.
[10] Giannouli, M., Di Popolo, A., Durante-Mangoni, E., Bernardo, M., Cuccurullo, S., Amato, G., Tripodi, M.F., Triassi, M. and Utili, R. (2012) Molecular Epidemiology and Mechansisms of Rifampicin Resistance in Acinetobacter baumannii Isolates from Italy. International Journal of Antimicrobial Agents, 39, 58-63.
[11] Koprnová, J., Svetlansky, I., Babel’a, R., Bilíková, E., Hanzen, J. and Zuscáková, I.J. (2001) Prospective Study of Antibacterial Susceptibility, Risk Factors and Outcome of 157 Episodes of Acinetobacter baumannii Bacteremia in 1999 in Slovakia. Scandinavian Journal of Infectious Diseases, 33, 891-895.
[12] Blot, S., Vandewoude, K. and Colardyn, F. (2003) Nosocomial Bacteremia Involving Acinetobacter baumannii in Critically Ill Patients: A Matched Cohort Study. Intensive Care Medicine, 29, 471-475.
[13] Cisneros, J.M. and Rodriguez-Bano, J. (2002) Nosocomial Bacteremia Due to Acinetobacter baumannii: Epidemiology, Clinical Features and Treatment. Clinical Microbiology and Infection, 8, 687-693.
[14] Tilley, P.A. and Roberts, F.J. (1994) Bacteremia with Acinetobacter Species: Risk Factors and Prognosis in Different Clinical Settings. Clinical Infectious Diseases, 18, 896-900.
[15] Chen, C.H., Lin, L.C., Chang, Y.J., Huang, C.C., Liu, C.E. and Young, T.G. (2003) Analysis of Prognostic Factors in 95 Patients with Acinetobacter baumannii Bacteremia. Infection, 31, 331-335.
[16] Nazir, J., Urban, C., Mariano, N., Burns, J., Tommasulo, B., Rosenberg, C., Segal-Nauer, S. and Rahal, J.J. (2004) Quinolone-Resistant Haemophilus influenzae in a Long-Term Care Facility: Clinical and Molecular Epidemiology. Clinical Infectious Diseases, 38, 1564-1569.
[17] Wehbeh, W., Rojas-Diaz, R., Li, X., Mariano, N., Grenner, L., Segal-Maurer, S., Tommasulo, B., Drlica, K. and Rahal, J.J. (2005) Fluoroquinolone-Resistant Streptococcus agalactiae: Epidemiology and Mechanism of Resistance. Antimicrobial Agents and Chemotherapy, 49, 2495-2497.
[18] Glew, R.H., Moellering, R.C. and Kunz, L.J. (1977) Infections with Acinetobacter calcoaceticus (Herellea vaginicola): Clinical and Laboratory Studies. Medicine, 56, 79-97.
[19] Park, J.H., Choi, S.H. and Chung, J.W. (2013) The Impact of Early Adequate Antimicrobial Therapy on 14-Day Mortality in Patients with Monomicrobial Pseudomonas aeruginosa and Acinetobacter baumannii Bacteremia. Journal of Infection and Chemotherapy, 19, 843-849.
[20] Kim, Y.J., Kim, S.I., Hong, K.W., Kim, Y.R., Park, Y.J. and Kang, M.W. (2012) Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy. Journal of Korean Medical Science, 27, 471-475.
[21] Lee, Y.T., Kuo, S.C., Yang, S.P., Lin, Y.T., Tseng, F.C., Chen, T.L. and Cho, W.L. (2012) Impact of Appropriate Antimicrobial Therapy on Mortality Associated with Acinetobacter baumannii Bacteremia: Relation to Severity of Infection. Clinical Infectious Diseases, 55, 209-215.
[22] Huang, S.T., Chiang, M.C., Kuo, S.C., Lee, Y.T., Chiang, T.H., Yang, S.P., Ti-Yin, Chen, T.L. and Fung, C.P. (2012) Risk Factors and Clinical Outcomes of Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia. Journal of Microbiology, Immunology and Infection, 45, 356-362.
[23] Anstey, N.M., Currie, B.J. and Withnall, K.M. (1992) Community-Acquired Acinetobacter Pneumonia in the Northern Territory of Australia. Clinical Infectious Diseases, 14, 83-91.
[24] Chen, M.Z., Hsueh, P.R., Lee, L.N., Yu, C.J., Yang, P.C. and Luh, K.T. (2001) Severe Community-Acquired Pneumonia Due to Acinetobacter baumannii. Chest, 120, 1072-1077.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.